CRL

Charles River Laboratories International, Inc.

October 5, 2026 · market open

Rarity

1.65

Peak move

+7.18%

Float cap

$14.1B

Charles River Laboratories International, Inc. is a non-clinical global drug development partner. It provides discovery and safety assessment services, both Good Laboratory Practice and non-GLP, as well as products and services for manufacturing. The company serves pharmaceutical and biotechnology clients, supporting target identification through non-clinical development.

• demand_signalOct 5

  Mizuho reported that biopharma sector funding totaled $13.0 billion in September 2026, up 56% year over year, a forward demand indicator for preclinical CRO services.

  Webes.investing.comWebfr.investing.com
• insider_saleOct 2 · 16:27 ET

  Charles River Laboratories disclosed in a Form 4 filed October 2, 2026 that EVP & CFO Glenn Coleman bought 10 shares at $297.43 per share on September 30, 2026, raising his direct holding to 27,762 shares.

  SEC4 0001100682-26-000144Webstockpage.10jqka.com.cnWebbasic.10jqka.com.cnWebbasic.10jqka.com.cn
• analyst_ratingOct 1 · 06:30 ET

  UBS resumed coverage of Charles River Laboratories with a Buy/strong buy rating and a $357 price target, citing over $40M of cost savings and about 160 basis points of DSA operating margin benefit from internalizing non-human primate supply, plus $0.64 of EPS accretion.

  Webmarketbeat.comWebes.investing.comWebin.investing.comWebdefenseworld.net
• investor_daySep 24

  At its 2026 Investor Day, Charles River Laboratories set 2030 targets of 5%-7% organic revenue growth, ~24% non-GAAP operating margin and low-double-digit non-GAAP EPS growth under its 'Pathway to Purpose' strategy, with its 'Create the Future' program targeting over $300M in cumulative savings from 2027-2030.

  Webnasdaq.com